Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.68 |
| ▸ | PNP | P00491 | 7/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | EDNRA | P25101 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23892740 | 0.87 | TK1 (0.70) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL669006 | 0.86 | TK1 (0.68) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL933142 | 0.84 | TK1 (0.67) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL874736 | 0.84 | PNP (0.64) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9960816 | 0.83 | PNP (0.68) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL29286376 | 0.83 | TK1 (0.76) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9663133 | 0.82 | TK1 (0.64) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL10506150 | 0.82 | TK1 (0.71) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL10506159 | 0.82 | TK1 (0.71) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9663138 | 0.82 | TK1 (0.64) | TK1PNPBLMUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157534-A | cDNA labelling control for single cell analysis | 贝克顿迪金森公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-114207154-A | Selective enrichment broth for detecting one or more pathogens | 波利斯科普实验室 | 2022-03-18 | — | — | CN | disclosed |
| CN-108300718-B | Modulation of androgen receptor expression | 苏州瑞博生物技术股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-113817735-A | Compounds and methods for modulating angiotensinogen expression | IONIS制药公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113710283-A | Compounds, methods and pharmaceutical compositions for modulating expression of DUX4 | 田边三菱制药株式会社 | 2021-11-26 | — | — | CN | disclosed |
| CN-113660946-A | IL-2 conjugates and methods of use thereof | 新索思股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-105377887-B | Compositions and methods for modulating apolipoprotein (a) expression | IONIS制药公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-111801417-A | Novel RNA-programmable endonuclease systems and their use in genome editing and other applications | 克里斯珀医疗股份公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-110268060-A | α -1 antitrypsin (AAT) RNAi agents, compositions comprising AAT RNAi agents, and methods of use | 箭头药业股份有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-110234326-A | Compositions and methods for inhibiting factor XII gene expression | 箭头药业股份有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-102549158-B | By suppressing to treat the disease that TFE3 is related to IRS albumen 2 (IRS2) for transcription factor E3 (TFE3) natural antisense transcript | 库尔纳公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-102947451-B | Treatment of ATOH1 related diseases by inhibition of natural antisense transcript to atonal homolog 1(ATOH1) | 库尔纳公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-102985543-B | Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4 | 库尔纳公司 | 2017-09-08 | — | — | CN | disclosed |
| CN-107072963-A | Therapeutic nanoparticles and related compositions, methods and systems | 吉倪塞思公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-102906264-B | Treatment of IRF8 related diseases by inhibition of natural antisense transcript to interferon regulatory factor 8(IRF8) | 库尔纳公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-106834291-A | Compositions and methods for inhibiting expression of transthyretin | 阿尔尼拉姆医药品有限公司 | 2017-06-13 | — | — | CN | disclosed |
| CN-106701757-A | Modulation of hsp47 expression | 日东电工株式会社 | 2017-05-24 | — | — | CN | disclosed |
| CN-102639151-B | Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG | 库尔纳公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-103635197-A | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) | EXCALLIARD PHARMACEUTICALS INC | 2014-03-12 | — | — | CN | disclosed |
| WO-2003070160-A2 | ANTISENSE MODULATION OF PROTEIN EXPRESSION | CURAGEN CORPORATION (US) | 2003-08-28 | — | — | WO | disclosed |